B. Bolon et al., Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis, MOL THER, 3(2), 2001, pp. 197-205
Osteoprotegerin (OPG) regulates bone resorption by inhibiting osteoclast fo
rmation, function, and survival. The current studies employed a mouse ovari
ectomy (OVX) model of estrogen deficiency to investigate gene therapy with
OPG as a means of preventing osteoporosis. Young adult females injected wit
h a recombinant adenoviral (Ad) vector carrying cDNA of either full-length
OPG or a fusion protein combining the hOPG ligand-binding domain with the h
uman immunoglobulin constant domain (Ad-hOPG-Fc) developed serum OPG concen
trations exceeding the threshold needed for efficacy. However, elevated cir
culating OPG levels were sustained for up to 18 months only in mice given A
d-hOPG-Fc. Administration of Ad-hOPG-Fc titers between 10(7) and 10(9) pfu
yielded dose-dependent increases in serum OPG. Mice subjected to OVX or sha
m surgery followed by immediate treatment with Ad-hOPG-Fc had significantly
more bone volume with reduced osteoclast numbers in axial and appendicular
bones after 4 weeks. In contrast, animals given OVX and either a control v
ector or vehicle had significantly less bone than did comparably treated sh
am-operated mice. This study demonstrates that a single adenoviral gene tra
nsfer can produce persistent high-level OPG expression and shows that gene
therapy to provide sustained delivery of OPG may prove useful in treating o
steoporosis.